Semaglutide's molecular formula and what it means in practice

Step 1: reading the formula, what those numbers represent

A molecular formula lists every atom in a single molecule. Semaglutide's (C₁₈₇H₂₉₁N₄₅O₅₉S) tells you there are 187 carbon atoms, 291 hydrogen atoms, 45 nitrogen atoms, 59 oxygen atoms, and one sulphur atom. The sheer count reflects the fact that semaglutide is not a small synthetic compound but a peptide: a chain of 34 amino acid residues built to mimic glucagon-like peptide-1 (GLP-1), a hormone your gut secretes naturally after eating.

Small-molecule drugs (think aspirin, at C₉H₈O₄) survive the stomach intact and cross into the bloodstream easily. Semaglutide, at roughly 4,114 daltons, sits in an entirely different category. If you want to go deeper on how size shapes drug behaviour, the question of whether semaglutide counts as a small molecule has its own answer. The short version: it does not, and that distinction drives most of the practical decisions around how it is given.

Novo Nordisk's chemists made two deliberate modifications to the natural GLP-1 sequence to turn a fleeting gut hormone into a weekly medicine. First, one amino acid (alanine at position 8) was swapped out to resist the enzyme DPP-4, which would otherwise degrade the molecule within minutes. Second, a C18 fatty-acid chain was attached via a linker to a lysine residue, and it is this chain that anchors the molecule to albumin in the blood, stretching its half-life from a couple of minutes (native GLP-1) to roughly one week.

Step 2: how the structure determines the route of administration

Because the semaglutide peptide is too large and too readily degraded by stomach acid to reach the bloodstream intact by conventional means, the weekly injection form (Wegovy) bypasses the gut entirely. The pre-filled pen delivers semaglutide subcutaneously, into fat tissue beneath the skin at the abdomen, thigh, or upper arm, from where it absorbs steadily. Wegovy's full profile, including its licensed dosing schedule in the UK, explains the practical side of that process.

The oral Wegovy tablet (approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management) solves the bioavailability problem differently. It co-formulates semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that temporarily makes the stomach lining permeable enough for the large peptide to cross. This is why the tablet must be taken first thing in the morning on an empty stomach with a small amount of plain water, waiting at least 30 minutes before food or drink, the window of permeability is short and any food or liquid closes it.

The molecular weight of semaglutide and the reasons it complicates oral delivery are explored in more detail separately, along with how that figure compares to other GLP-1 medicines now available in the UK.

Step 3: what the fatty-acid chain means for how you experience treatment

The albumin-binding side chain does more than extend duration. Because semaglutide remains in circulation for roughly seven days, a single weekly dose produces a relatively smooth pharmacological effect rather than the peaks and troughs associated with shorter-acting compounds. That stability is part of why gradual titration (starting low and stepping up over several months) can manage side effects; the molecule's slow elimination gives the body time to adjust between increases.

Most side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and sometimes vomiting. They tend to be most noticeable at the start of treatment or after a dose step, and they settle for many people within a week or two as the system adapts. The BNF's prescribing reference for semaglutide lists the full adverse-effect and interaction profile that clinicians consult before and during treatment.

Severe, persistent stomach pain that spreads to the back needs prompt medical assessment, it can be a sign of pancreatitis, which the MHRA flagged in a January 2026 Drug Safety Update on GLP-1 medicines. Any suspected side effect can be reported directly at Yellow Card. Worth knowing before you start.

Step 4: from chemistry to clinical suitability

Understanding semaglutide's structure is genuinely useful background, it explains why the tablet's morning routine is non-negotiable, why the injection schedule is weekly rather than daily, and why neither form is something you simply pick up at a counter. The molecule's design is inseparable from the clinical protocols around it.

Semaglutide as Wegovy is licensed in the UK for adults with a BMI of 30 or above, or from 27 upwards where a weight-related condition is present. A prescriber considers the full picture (current medicines, medical history, lifestyle) before the formula makes it into a treatment plan. Our weight-loss treatment overview covers how that assessment works in plain terms. If you are thinking about the cost side of things, the UK pricing context for Wegovy is worth reading before drawing conclusions from headlines.

The three-dimensional structure of semaglutide goes a level further if the chemistry interests you, showing how the fatty-acid tail actually folds around albumin and what that means for receptor binding. And for a broader look at the molecule in context, the semaglutide molecule overview draws the threads together.

If you have read enough and want a clinical view of whether semaglutide is right for you, speak to our prescribers, a named clinician, not a piece of software, reviews every consultation the same day.